drugset / Trial / NCT02509923

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

NCT02509923

Phase 1 Completed 54 enrolled Zeria Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate pharmacokinetics and pharmacodynamics of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium (10 mg, 20 mg ) in Healthy Male Subjects. And to evaluate food-effect in Healthy Male Subjects administrated Z-215 20 mg.

Timeline

Start
2015-07
Primary completion
2016-03
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZELOPRAZOLE Small molecule 10 mg
Subject AZELOPRAZOLE Small molecule 20 mg
Subject AZELOPRAZOLE Small molecule 40 mg
Subject Rabeprazole Small molecule 10 mg
Subject Rabeprazole Small molecule 20 mg

Indications

No indication recorded.